{{medical}}{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477172835
| IUPAC_name = 1,3-thiazol-5-ylmethyl ''N''-[(2''S'',3''S'',5''S'')-3-hydroxy-5-[(2''S'')-3-methyl-2-<nowiki/>{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate
| image = Ritonavir structure.svg
| width = 275
| image2 = Ritonavir ball-and-stick.png

<!--Clinical data-->
| tradename = Norvir
| Drugs.com = {{drugs.com|monograph|ritonavir}}
| MedlinePlus = a696029
| pregnancy_AU = B3
| pregnancy_US = B
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 98-99%
| metabolism = Hepatic
| elimination_half-life = 3-5 hours
| excretion = mostly fecal

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 155213-67-5
| ATC_prefix = J05
| ATC_suffix = AE03
| ATC_supplemental =  
| PubChem = 392622
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00503
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 347980
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O3J8G9O825
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00427
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 45409
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 163
| NIAID_ChemDB = 028478

<!--Chemical data-->
| C=37 | H=48 | N=6 | O=5 | S=2 
| molecular_weight = 720.946 g/mol
| smiles = CC(C)c4nc(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)cs4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NCDNCNXCDXHOMX-XGKFQTDJSA-N
}}
<!-- Definition and medical uses -->
'''利托那韋'''，市面販售藥名為'''Norvir'''，是一種[[抗反轉錄病毒藥物|抗反轉錄病毒藥物]] ，和其他藥物共同治療[[愛滋病|愛滋病]]。<ref name=AHFS2015>{{cite web|title=Ritonavir|url=http://www.drugs.com/monograph/ritonavir.html|publisher=The American Society of Health-System Pharmacists|accessdate=Oct 23, 2015}}</ref> 這樣的治療方式被稱作高效能抗反轉錄病毒療法(HAART).<!-- <ref name=AHFS2015/> --> -通常低劑量利托那韋會搭配[[蛋白酶抑制劑|蛋白酶抑制劑]]使用。<!-- <ref name=AHFS2015/> --> 一般為口服使用<ref name=AHFS2015/>

<!-- Side effects and mechanism -->
常見的副作用包含噁心、嘔吐、喪失食慾、腹瀉及手足麻木感 <!-- <ref name=AHFS2015/> -->，嚴重的副作用包含引起肝臟問題、[[胰腺炎|胰臟炎]]、過敏、引起心律不整。<!-- <ref name=AHFS2015/> -->；同時服用利托那韋與[[胺碘酮|胺碘酮]]或辛伐他汀可能導致嚴重的藥物交互影響<ref name=AHFS2015/>，目前認為懷孕患者使用低劑量是安全無虞的 <ref>{{cite web|title=Ritonavir Pregnancy and Breastfeeding Warnings|url=http://www.drugs.com/pregnancy/ritonavir.html|website=drugs.com|accessdate=23 October 2015}}</ref> 。利托那韋屬於蛋白酶抑制劑類 <ref name=AHFS2015/>，常用於抑制將其他代謝蛋白酶的酶運作 <!-- <ref name=BNF69/> -->，這種抑制機制導致藥性以更高濃度呈現<ref name=BNF69>{{cite book|title=British National Formulary 69|date=March 31, 2015|publisher=Pharmaceutical Pr|isbn=9780857111562|page=426|edition=69}}</ref>。

<!-- Society and culture -->
利托那韋首次發現於1996年 <ref>{{cite book|last1=Hacker|first1=Miles|title=Pharmacology principles and practice|date=2009|publisher=Academic Press/Elsevier|location=Amsterdam|isbn=9780080919225|page=550|url=https://books.google.ca/books?id=5YDMmjWXe-AC&pg=PA550}}</ref>，在最基本的健康照護系統中最必要的藥物清單[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]登錄有案 <ref>{{cite web|title=WHO Model List of EssentialMedicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013}}</ref> 膠囊藥劑的藥效與藥片並不相同 <ref name=AHFS2015/>，全球的批發成本大約是每日0.07至2.20美金左右 <ref name=ERC2014>{{cite web|title=Ritonavir|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RIT100T&s_year=2014&year=2014&str=100%20mg&desc=Ritonavir&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E4%2E2%2E3&supplement=&class_name=%2806%2E4%2E2%2E3%29Protease%20inhibitors%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=23 October 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20170510104628/http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=RIT100T&s_year=2014&year=2014&str=100%20mg&desc=Ritonavir&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E4%2E2%2E3&supplement=&class_name=%2806%2E4%2E2%2E3%29Protease%20inhibitors%3Cbr%3E|archivedate=2017年5月10日}}</ref>，在美國，一劑大約在9.20到55美元之間，依劑量而定<ref name=AHFS2015/>

==醫學應用==
利托那韋常用於治療[[愛滋病|愛滋病]].<ref name=AHFS2015/>

==副作用==
當使用利托那韋治療[[愛滋病|愛滋病]]，在給予足夠劑量後，往往會產生下列副作用。2015年之後，利托那韋僅用作為藥動學上的抑制因子，因此都僅施打低劑量。使用低劑量後，副作用明顯減少。<ref>[http://www.rxlist.com/cgi/generic/ritonavirsol_ad.htm Norvir] {{webarchive|url=https://web.archive.org/web/20070627024638/http://www.rxlist.com/cgi/generic/ritonavirsol_ad.htm |date=2007-06-27 }}, rxlist.com</ref>
* 倦怠
* 腹瀉
* 噁心嘔吐
* 腹痛
* 頭暈
* 失眠
* 盜汗
* 味覺異常
* [[高膽固醇血症|高膽固醇血症]]
* [[高血糖|高血糖]]
* 高[[轉氨酶|轉氨酶]]
* 高[[肌酸激酶|肌酸激酶]]

==參考文獻==
{{reflist|32em}}

==進階閱讀==
* {{cite journal | doi = 10.1021/op000023y | title = Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development | year = 2000 | last1 = Chemburkar | first1 = Sanjay R. | last2 = Bauer | first2 = John | last3 = Deming | first3 = Kris | last4 = Spiwek | first4 = Harry | last5 = Patel | first5 = Ketan | last6 = Morris | first6 = John | last7 = Henry | first7 = Rodger | last8 = Spanton | first8 = Stephen | last9 = Dziki | first9 = Walter | last10 = Porter | first10 = William | last11 = Quick | first11 = John | last12 = Bauer | first12 = Phil | last13 = Donaubauer | first13 = John | last14 = Narayanan | first14 = B. A. | last15 = Soldani | first15 = Mauro | last16 = Riley | first16 = Dave | last17 = McFarland | first17 = Kathyrn | journal = Organic Process Research & Development | volume = 4 | issue = 5 | pages = 413| display-authors = 8 }}

==外部連結==
* [https://web.archive.org/web/20091109040634/http://www.pubpk.org/index.php?title=Ritonavir PubPK - Ritonavir pharmacokinetics]
* [https://web.archive.org/web/20131205172431/http://www.abbvie.com/index.html] (manufacturer's website)
* [http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=RIT Ritonavir bound to proteins] in the [[Protein_Data_Bank|PDB]]
* [http://www.rxabbvie.com/pdf/norvirtab_pi.pdf Norvir Prescribing Information]

{{HIVpharm}}
{{RNA antivirals}}
{{Cytochrome P450 modulators}}

[[Category:Breakthrough_therapy|Category:Breakthrough therapy]]
[[Category:Carbamates|Category:Carbamates]]
[[Category:HIV_protease_inhibitors|Category:HIV protease inhibitors]]
[[Category:RTT|Category:RTT]]
[[Category:Thiazoles|Category:Thiazoles]]
[[Category:Ureas|Category:Ureas]]
[[Category:World_Health_Organization_essential_medicines|Category:World Health Organization essential medicines]]